A breakthrough vaccine technology developed with the help of artificial intelligence (AI) is raising hopes that future pandemics could be prevented before they begin, potentially saving millions of lives and reducing the need for widespread lockdowns.
Researchers at the University of Cambridge and biotechnology company DIOSynVax have developed a new type of vaccine designed to provide protection against entire families of viruses rather than a single strain.
The innovation has completed its first human safety trial, marking a significant milestone in vaccine development.
Unlike conventional vaccines, which are typically updated in response to emerging variants, the new approach uses machine learning to analyse vast databases of viral genetic sequences gathered through global surveillance programmes.
The AI identifies the core biological features that viruses depend on to survive and combines them into what researchers describe as a “super-antigen.”
The goal is to train the immune system to recognise characteristics shared across an entire virus family, enabling protection not only against existing strains but also against future mutations that have yet to emerge.
Professor Jonathan Heeney of the University of Cambridge’s Department of Veterinary Medicine said the technology represents a major shift in vaccine design.
“What the COVID pandemic taught us is how fast we can make vaccines, but we’re still using the old paradigm. This is about making one vaccine that will get them all based on their relationships,” he said.
Related:
- The Role of AI in Genomics: Unlocking the Power of Genetic Data
- Africa CDC and Ethiopia Deepen Collaboration on AI and Digital Health
The first Phase I clinical trial involved 49 healthy volunteers aged between 18 and 50 in Cambridge and Southampton. Researchers reported that the vaccine demonstrated a strong safety profile while generating immune responses against multiple coronaviruses.
According to the findings, the vaccine triggered immune responses against SARS-CoV-2, the virus responsible for COVID-19, the original SARS virus, and related bat coronaviruses that scientists believe could potentially spill over into human populations in the future.
The vaccine is administered using a needle-free microfluidic jet system that delivers genetic instructions directly into skin cells through a high-pressure stream of liquid.
Researchers say the approach could simplify vaccine delivery and improve acceptance among people who are reluctant to receive injections.
Following the successful completion of the initial trial, researchers are preparing a larger Phase II study expected to involve more than 200 participants to further assess the vaccine’s effectiveness.
Scientists believe the technology could transform the current reactive approach to disease prevention, which often requires new vaccines to be developed after outbreaks occur.
By targeting features shared across entire virus families, the platform could provide broad protection against thousands of potential variants.
The research team is already exploring the use of the same AI-powered platform to develop vaccines against other major infectious threats, including Ebola and avian influenza.
Heeney said the technology could significantly strengthen global preparedness for future outbreaks.
“We believe this can be a game-changer. It has the potential to make vaccines far better, broader, and capable of providing more robust protection against future threats,” he said.
While further clinical trials and regulatory reviews remain necessary, public health experts say the early results demonstrate how AI could help reshape vaccine development and strengthen the world’s ability to prevent future pandemics before they escalate into global crises.
Senior Reporter/Editor
Bio: Ugochukwu is a freelance journalist and Editor at AIbase.ng, with a strong professional focus on investigative reporting. He holds a degree in Mass Communication and brings extensive experience in news gathering, reporting, and editorial writing. With over a decade of active engagement across diverse news outlets, he contributes in-depth analytical, practical, and expository articles exploring artificial intelligence and its real-world impact. His seasoned newsroom experience and well-established information networks provide AIbase.ng with credible, timely, and high-quality coverage of emerging AI developments.